In this article
FDA Updates Indication for Pembrolizumab in Gastric Cancer
The Food and Drug Administration updated the approved use of pembrolizumab (Keytruda, Merck) in combination with trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for treating HER2-positive gastric or gastroesophageal junction adenocarcinoma that is locally advanced, unresectable, or metastatic in patients who have not received prior treatment. The revised approval limits the use of this indication to patients with tumors expressing PD-L1 (CPS ≥ 1) as detected by an FDA-approved test while still complying with accelerated approval regulations.
Companion Diagnostic for PD-L1 Expression
The FDA approved the Agilent PD-L1 IHC 22C3 pharmDx as a companion diagnostic device for identifying patients with gastric or GEJ adenocarcinoma whose tumors have PD-L1 expression (CPS ≥ 1).
KEYNOTE-811 Clinical Trial Results
The effectiveness was assessed in KEYNOTE-811 (NCT03615326), a study conducted at many centers, where patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had not undergone systemic therapy for metastatic illness were randomly assigned to receive either the treatment or a placebo in a double-blind manner. Patients were randomly assigned to receive either pembrolizumab 200 mg intravenously or a placebo every 2 weeks along with trastuzumab and either fluorouracil plus cisplatin or capecitabine plus oxaliplatin in a 1:1 ratio.
The primary effectiveness endpoints of KEYNOTE-811 are overall survival (OS) and progression-free survival (PFS). The approval on May 5, 2021, was granted after evaluating the interim analysis of objective response rate (ORR) and duration of response (DOR). ORR and DOR were evaluated in the initial 264 randomized participants at that time. The objective response rate (ORR) was 74% (95% CI: 66, 82) in the pembrolizumab plus chemotherapy group and 52% (95% CI: 43, 61) in the placebo plus chemotherapy group (p-value <0.0001). The median duration of response was 10.6 months (range: 1.1 to 16.5) and 9.5 months (range: 1.4 to 15.4) in the different groups.
An interim analysis of a fully enrolled trial with 698 participants showed that in a subset of 104 patients with PD-L1 CPS <1, the hazard ratios (HR) for overall survival (OS) and progression-free survival (PFS) were 1.41 (95% CI 0.90, 2.20) and 1.03 (95% CI 0.65, 1.64) respectively.
Safety Profile and Patient Tolerance
The safety profile of patients treated with pembrolizumab and trastuzumab + chemotherapy in KEYNOTE-811 was similar to the established safety profiles of trastuzumab + chemotherapy alone or pembrolizumab monotherapy.
Recommended Dosage and Administration
The suggested dosage of pembrolizumab is 200 mg every 3 weeks or 400 mg every 6 weeks until disease progression, intolerable toxicity, or a maximum of 24 months. Administer pembrolizumab before trastuzumab and chemotherapy if they are given on the same day.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.